In the final episode, Shaping the Future of Immunotherapy in NSCLC, the panelists explore the following critical questions: Which additional data would you like to see with immunotherapies used in NSCLC? What is the relevance of the EMPOWER-Lung 3 for patients and payors? How do you see the future management of NSCLC evolving with immunotherapies and do you see a potential role for extended dosing?
In this episode, Optimizing Immunotherapy Selection and Safety Management in NSCLC, the panelists explore the following questions: How are you deciding between available immunotherapies in NSCLC, both as monotherapies and in combination with chemotherapy? What are your current protocols for monitoring and managing adverse events associated with immunotherapies? Does the consistent adverse event profile with cemiplimab plus chemotherapy over 5 years increase this regimen’s clinical value?
This episode, titled Interpreting EMPOWER-Lung 3: Key Endpoints and Confidence in Cemiplimab-Based Therapy, features lung cancer experts answering the following critical questions: What are your main takeaways from the data covered? Which of the endpoints examined are most important for your clinical practice and why? Does the consistent benefit with cemiplimab plus chemotherapy across the different subgroups increase your confidence?
In Applying EMPOWER-Lung 3 to Clinical Practice: Population Relevance, Histology, and PD-L1 Considerations, our panel delve into the following critical questions: Is the study population similar to what you see in your clinical practice and why is this an important group to examine? Why was it important to delineate between squamous and non-squamous histologies? How does the level of PD-L1 expression impact your management decisions in patients with NSCLC?
In this episode, Checkpoint Inhibitors in NSCLC: FDA-Approved Immunotherapies, Pivotal Trials, and Insights from EMPOWER-Lung 3, the lung cancer experts explore the following questions: What are the FDA-approved immunotherapies for NSCLC and can you provide a high-level overview of the clinical trials that led to their approval? What was the key background information from EMPOWER-Lung 3?
Experts reviews how NSCLC was historically treated with chemotherapy, radiation, and surgery, highlights the limitations and unmet needs of those approaches, and explains how these challenges led to the development of immunotherapies to improve patient outcomes.
